Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

HK Inno.N (195940 KS): Mixed 2Q Result; Pipeline Progress to Maintain Positive Momentum

HK Inno. N (195940 KS): Promising US Trial Result for K-CAB Raises Hope; Starts 2025 on Strong Note

HK Inno.N (195940 KS): Prescription Drugs Drive 4Q25 Result; Maiden US Approval on Card

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hk-inno-n-corp" target="_blank" data-smartkarma-citation="entities:33522:1" rel="noopener">HK inno.N (195940 KS)</a> reported 1Q26 result, with all key parameters showing improvement compared to year-ago period. Continued strong sales of mainstay prescription drug business remained the key driver.</li>
<li>Significant improvement in profitability, driven by double-digit growth in major prescription drug products, along with strong growth in K-CAB China royalty, is the key highlight of 1Q26 result.</li>
<li>HK inno is expected to maintain growth momentum, with U.S. approval of K-CAB being the next catalyst. The company is strengthening prescription drug business and innovative drug pipeline beyond K-CAB.</li>
</ul>



HK inno.N (195940 KS) reported 1Q26 result, with all key parameters showing improvement compared to year-ago period. Continued strong sales of mainstay prescription drug business remained the key driver.
Significant improvement in profitability, driven by double-digit growth in major prescription drug products, along with strong growth in K-CAB China royalty, is the key highlight of 1Q26 result.
HK inno is expected to maintain growth momentum, with U.S. approval of K-CAB being the next catalyst. The company is strengthening prescription drug business and innovative drug pipeline beyond K-CAB.


HK Inno.N (195940 KS): Modest Show In 1Q26; All Eyes on Maiden US Approval; Strengthening Pipeline